Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 13, 2015 7:38 PM ET


Company Overview of BioTime, Inc.

Executive Profile

Pedro Lichtinger

Chief Executive Officer of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics Inc, BioTime, Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Pedro Lichtinger has been the Chief Executive Officer and President of Asterias Biotherapeutics, Inc. since June 09, 2014. Mr. Lichtinger served as the Chief Executive Officer and President of Optimer Pharmaceuticals, Inc. from May 2010 to February 2013. Mr. Lichtinger served as an Executive of Pfizer, Inc. from 1995 to 2009 and as the President of Pfizer's Global Primary Care Business Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global ...

Corporate Headquarters

1301 Harbor Bay Parkway
Alameda, California 94502

United States

Phone: 510-521-3390
Fax: 510-521-3389

Board Members Memberships

Member of Board of Governors
Chief Executive Officer, President and Director


MBA 1978
University of Pennsylvania - The Wharton School
Universidad Nacional Autónoma de México

Other Affiliations

Annual Compensation

Total Annual Compensation$224,359

Stocks Options

Restricted Stock Awards$468,000
All Other Compensation$8,333
Exercisable Options$125,000
Unexercisable Options$875,000
Total Number of Options$1,000,000

Total Compensation

Total Annual Cash Compensation$270,942
Total Short Term Compensation$224,359
Other Long Term Compensation$476,333
Total Calculated Compensation$2,172,229

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Olav Hellebø Chief Executive Officer and Director
ReNeuron Group plc
John A. Scarlett M.D.Chief Executive Officer, President and Director
Geron Corporation
Paul K. Wotton Ph.D.Chief Executive Officer, President and Director
Ocata Therapeutics, Inc.
Yokoyama Chikafumi Ph.D.Chief Executive Officer, President and Representative Director
ReproCELL, Inc.
Keith Murphy Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee
Organovo Holdings, Inc.
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioTime, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at